All rights reserved. No reuse allowed without permission.

1

# **TITLE PAGE**

2 Title:

3 "Urban Tertiary Care Centre Experience of Characteristics of Severe COVID-19 Pneumonia"

- 4 **RUNNING TITLE: Characteristics of Severe COVID**
- TYPE OF MANUSCRIPT: ORIGINAL ARTICLE 5

#### Authors: 6

- 1. Dr. Nehal M Shah MD (Medicine) 7
- 8 Assistant Professor
- 9 Department of Medicine, SVP hospital,
- SMT NHL Municipal Medical College, Ellisbridge, Ahmedabad-380006. 10
- 11 M. 9898286644
- Email: drnehalshah1929@gmail.com 12
- 2. Dr. Janakkumar R Khambholja MD (Medicine) 13
- Professor 14
- Department of Medicine, SVP hospital, 15
- SMT NHL Municipal Medical College, Ellisbridge, Ahmedabad-380006. 16
- M. 9825447813 17
- Email: drjanak.research@gmail.com 18
- 19 3. Dr. Nilay Suthar MD (Medicine)\* (Corresponding Author)
- 20 Professor
- Department of Medicine, SVP hospital, 21
- SMT NHL Municipal Medical College, Ellisbridge, Ahmedabad-380006 22
- 23 M. 9825295840
- Email: nilaysuthar@gmail.com 24
- 4. Dr. Hemant Tiwari PhD (Population Sciences) 25
- SMT NHL Municipal Medical College, Ellisbridge, Ahmedabad 26
- 27 M. 6354929539
- Email:tiwarihemant1@rediffmail.com 28
- 5. Dr. Vandit Desai (MBBS), 3<sup>RD</sup> year resident, 29
- 30 SMT NHL Municipal Medical College, Ellis bridge, Ahmedabad—380006.
- M-9825493960 31
- Email: blackbuck3@gmail.com 32
- 6. Dr. Vishal Beriwala (MBBS), 2<sup>nd</sup> year resident, 33
- SMT NHL Municipal Medical College, Ellis bridge, Ahmedabad—380006. 34
- M-8511773245 35
- Email:vishal.r.beriwala@gmail.com 36
- 37
- \*Corresponding Author: 38
- Dr. Nilay N Suthar MD (Medicine) 39
- 40
- Professor of Medicine NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
- Department of Medicine, 41

- All rights reserved. No reuse allowed without permission.
- 42 SMT NHL Municipal Medical College& SVP Institute of Medical & Scientific Research,
- 43 Ellisbridge, Ahmedabad-380006.
- 44 M. 9825295840
- 45 Email: <u>nilaysuthar@gmail.com</u>
- 46 Total number of pages: 15
- 47 Total number of figures: 5
- 48 Word counts for abstract: 265
- 49 Word counts for the text (excluding the references, tables and abstract): 2915
- 50 Word counts for introduction:72
- 51 Word counts for discussion: 930
- 52 Funding source: No FUNDING RECEIVED

Acknowledgment: Authors would like to thank Dr. Pratik Patel, The Dean Smt NHL Municipal Medical College, Dr. Sundeep Malhan, The Medical Superintendent, SVPIMSR and Dr. Ami Parikh, HOD, Dept. of Medicine, Smt NHL Municipal Medical College for their constant guidance and support. We also acknowledge residents of our unit for their contribution in gathering data. We are thankful to our esteemed patients.

- 59 Any Presentation Previously Done?: None
- 60 Registration number: Not Applicable
- 61 Conflict of Interest: None to Disclose from Any Author
- 62
- 63
- 64

#### 65 **TITLE:**

# 66 Urban Tertiary Care Centre Experience of Characteristics of Severe COVID-19

- 67 **Pneumonia**
- 68 Abstract:
- 69 Introduction:

The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, in December 2019, and has since spread worldwide.<sup>[1]</sup> This study attempts to summarize current evidence regarding major inflammatory markers, severity predictors and its impact on outcome,

vhich provide current clinical experience and treatment guidance for this novel coronavirus.

# 75 Methods:

This is a retrospective observational study done at an urban teaching covid-19 designated hospital. Hospital data were analysed with aim of studying inflammatory markers, predictors and outcome. Patients were classified in Mild, Moderate, Severe & Critical categories of COVID cases. Their clinical parameters, laboratory investigations, radiological findings & Outcome measures were studied. Strength of association & correlation of those parameters with severity and in-hospital mortality were studied.

82 **Results:** 

A total 204 (N) patients were clinically classified into different severity groups, as per 83 84 MOHFW and qCSI(quick Covid Severity Index) guidelines, as Mild (34), Moderate (56), Severe (39) and Critical (75). The mean(SD) age of the cohort was 55.1+13.2 years; 74.02% 85 86 were male. Severe COVID-19 illness is seen more in patients more than 50 years of age. COVID-19 patients having IHD develop worse disease with excess early in-hospital mortality. 87 88 Respiratory rate & Heart Rate on admission are correlated with severe and stormy disease. Among Inflammatory markers, on admission LDH, D-Dimer and CRP are related with severity 89 and excess in-hospital death rate. 90

# 91 **Conclusion:**

Advanced age, male gender, IHD, Respiratory Rate & Heart Rate on admission were associated
with severe covid-19 illness. S. Lactate Dehydrogenase & D-dimer was associated with severe
covid-19 illness and early in-hospital death.

# 95 Keyword:

96 Severe COVID-19 Pneumonia, ARDS, Inflammatory Markers, Adjunct Treatment

# 97 **INTRODUCTION:**

The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, in December 2019, and has since spread worldwide.<sup>[1,2]</sup> The viral genome of SARSCoV-2 was rapidly sequenced to enable diagnostic testing, epidemiologic tracking, and development of preventive and therapeutic strategies.<sup>[3]</sup>This study attempts to summarize current evidence regarding major inflammatory markers, severity predictors clinical experience and treatment guidance for this pandemic coronavirus.

# 105 **METHODS**:

- This is a retrospective observational study conducted at a tertiary care Ahmedabad Municipal Corporation run COVID-19 designated hospital. Cases were enrolled from Hospital Computerised Data Management System from June 2020 to August 2020. Cases with Different severity of COVID-19 patients were classified according to institutional SOP, as per guidance
- 110 from MOHFW<sup>[4]</sup>.

No 24-30/ Nasal	>30/ Mask	HFNC/NIV/IMV
prongs	<u>&gt;</u> 50/ Widsk	
90-94	<90	<90
2-4 L/min	<u>&lt;</u> 10 L/min	>10 L/min
	90-94	90-94 <90

111 Case definitions:[4,5]

Patients were studied for baseline characteristics, laboratory and radiological characteristics. This study attempts to summarize current evidence regarding major inflammatory markers, severity predictors and its impact on outcome, which provide current clinical experience and treatment guidance for this novel coronavirus. Study looked at outcomes as Death or Discharge and studied its association with several possible predictors. In-hospital mortality was defined as death during hospitalisation for covid-19 illness. Correlation with severity and in-hospital death were also accessed.

# 119 Statistical analysis:

Looking to approximately twenty per cent of in-hospital mortality rate in covid-19 cases<sup>[6,7]</sup>, 120 80% of Power of study & Two sided alpha error of 5%, required sample size is 193. Keeping 121 in view several possibilities we kept effective sample size of 204 for the current study. 122 Normality of the distribution was tested and Kurtosis was calculated. Categorical variables are 123 reported as number (%). Normally distributed continuous data were reported as mean  $\pm$ 124 standard deviation (SD).Nonparametric data were analysed by Chi square method. Parametric 125 data were analysed by standard students t test and ANOVA. Pearson Correlation was used 126 127 wherever applicable. Binary Logistic Regression was applied for predicting dichotomous binary dependant outcomes. Receiver operating characteristic(ROC) curves were used to 128 evaluate the potential predictive value of inflammatory markers on prognosis of hospitalised 129 COVID-19 patients. The Hosmere-Lemeshow test was used to calibrate the ROC curves. 130 Statistical software were used as per necessity like SPSS v25/v26, GraphPad Prism, MedCalc& 131 MS Excel 365. P-values less than 0.05 were considered as statistically significant difference. 132

# 133 **RESULTS:**

This is an observational study conducted at a tertiary care urban teaching hospital. The studypopulation characteristics and number can be inferred from Figure-1.

# 136 **Baseline characteristics:**

# 137 1. Age and Gender:

Study period was done from June 2020 to August 2020. All the data of vitals, radiological 138 and pathological tests, clinical notes and relevant treatment records of hospitalized confirmed 139 COVID-19 adult patients were documented to iHIS, which were transferred to Google forms 140 for data collection. Data entry and cross verification of each record were done to minimise 141 142 human errors. A total 204 (N) patients were studied, and they were clinically classified into different severity groups, as per MOHFW and qCSI (quick Covid Severity Index) guidelines, 143 as Mild (34), Moderate (56), Severe (39) and Critical (75), The mean(SD) age of the cohort 144 was 55.1+13.2 years; 74.02% were male. When we considered age group more than 50 years, 145 it comprises maximum Critical (37%) cases followed by Moderate (17%) illness compared to 146 patients aged less than 50 years of age. 65 % of cases were aged more than 50 years of age 147 (*P*=0.024). 148

Furthermore, these four clinical categories ie: mild, moderate, severe and critical were clubbed to sub-groups. 'NonSevere' cases are in Gr-A, 'Severe & Survived' cases are in Gr-B and 'Severe & NonSurvived' are in Gr-C (Table-1.1) When considering 50 years as the cut-off, patients more than 50 years had higher pulmonary compromise in the form of higher need of oxygen or assistive mechanical ventilator support. (P < 0.001)

# 154 2. Co-morbidities, vitals, blood groups & COVID Illness:

Gr-B and Gr-C cases had more Hypertension (HTN) than Gr-A. Type II diabetes (DM) did not have significant difference between both groups. However, *P*-value (0.0140) was observed to be statistically significant among Ischemic Heart Disease patients' groups.

Among the vitals on admission of these patients, we found that the difference between the mean Respiratory Rate (*P*-value= 0.0100) was statically significant between both groups but Heart Rate (*P*-value=0.0644) was not. Blood Group analysis of these patients showed that highest cases of covid-19 pneumonia had B Positive blood group followed by O positive, A positive and AB positive.

163 NonSevere (Gr-A), Severe & Survived (Gr-B) and Severe &NonSurvived (Gr-C) Sub-

164 Group Patients' analysis:

The overall age difference in the mean age between the groups (Gr-A, Gr-B &Gr-C) 165 was found to be highly statistically significant (P < 0.001) in our study population. In between 166 these three groups, we compared the mean difference of age among different age groups, but 167 only the mean difference was statistically significant, in the age group of less than 50 years, 168 between Gr-B and Gr-C. Population aged more than 50 years of age have higher chances of 169 170 having severe form of COVID-19 pneumonia [n=83(61%)] compared to Gr-A disease [n=52(39%)] which is statistically significant (P=0.023). But, among patients aged >50 years, 171 male gender has a higher chance of developing severe form of covid-19 illness compared to 172 female gender [59(44%) vs 24(18%)]. Although it was statistically not significant (P=0.619). 173

174 When we studied correlation of blood groups with the severity, it was observed in 175 current study population that it was statistically highly significant between Gr-A vs Gr-C 176 (P=0.019) and Gr-B vs Gr-C (P=0.025).

Among Gr-C patients, the commonest comorbidity observed is Hypertension (HTN) (67%) followed by Diabetes Mellitus (DM) (41%) and then Ischemic Heart Diseases (IHD) (33%). Although, the findings were statistically significantly associated with clinical severity only in case of IHD (P=0.002). On Admission Respiratory Rate (RR) and SpO<sub>2</sub> were found statistically significant as overall clinical severity of covid-19 cases and among Gr-A vs Gr-B and Gr-B vs Gr-C. Rest of other observed clinical signs were not found to have significance

# 183 Measured Laboratory Parameters& Chest X-rays:

We observed several laboratory parameters at the time of hospital admission and during hospital course. Table-2 describes the detailed observations in various clinical categories. The mean Haemoglobin, Platelet count & total white blood cell count were not much different in all the categories on admission. The NLR (Neutrophil- Lymphocyte Ratio) was higher among the severe and critical categories of cases. All other observed laboratory parameter were found statistically not significant among these four categories.

Chest X-rays of Severe and Critical COVID-19 patients had findings of bilateral ground
glass opacities with patchy consolidations; 26% in Critical covid-19 cases and 13% in severe
covid-19 cases. Although this finding was found to be statistically not significant.

# 193 Inflammatory markers and Clinical Severity in COVID-19 Pneumonia:

Figure-2 depicts the trend of various inflammatory markers and its association with clinical severity (Gr-A, Gr-Band Gr-C) over one week since admission. It has been observed that overall CRP remained elevated in Gr-C COVID 19 pneumonia patients in comparison with

197 Gr-A & Gr-B patients (Figure-2). It was observed that in reference to Gr-C patients, CRP-D7 198 is significantly high compared to Gr-A patients (OR= 1.03, CI: 1.004-1.067, P=0.027). On 199 studying the statistical correlation of CRP values with Gr-C category of COVID-19 illness, 200 89.3% of variance (R<sup>2</sup>=0.893) can be explained by variance in CRP.

In reference to D-Dimer values, D-Dimer remained elevated in Gr-C COVID 19 pneumonia patients in comparison with Gr-A and Gr-B patients. It was observed that in reference to Gr-A patients, D-Dimer-D7 is statistically significant in-Gr-C patients (OR= 1.42, CI: 1.100-1.836, P=0.007). On studying the statistical correlation of D-Dimer values with Gr-C category of COVID-19 illness, 68.2% of variance (R<sup>2</sup>=0.682) can be explained by variance in D-Dimer values.

In reference to S. Ferritin values, S. Ferritin remains elevated in Gr-C patients in comparison with Gr-A and Gr-B patients. On studying the statistical correlation of S. Ferritin values with Gr-C category of COVID-19 illness, only 29% of variance ( $R^2=0.290$ ) can be explained by variance in S. Ferritin values. When values of S. Ferritin plotted with dichotomous outcomes (Death or Discharge) 88.5% variance ( $R^2=0.885$ ) in outcome would have explained by S. Ferritin values over Day-0 to Day-7, i.e. First week of COVID-19 hospitalization.

In reference to LDH values, LDH remains elevated in Gr-C patients. It was observed 213 that in reference to Gr-A patients, LDH -D7 and LDH-D1 was associated statistically 214 significantly with Gr-C patients with OR= 1.01, CI: 1.008-1.024, p<0.001 and OR= 1.01, CI: 215 1.003-1.020, P=0.007 respectively. On studying the statistical correlation of LDH values with 216 Gr-C category of COVID-19 illness, 77.1% of variance in Severity (R<sup>2</sup>=0.771) could be 217 explained by variance in LDH values. When comparing these four common inflammatory 218 markers with dichotomous outcome (Death vs Discharge), it has been observed that trend of 219 LDH and S.CRP values found to explain more than 85% variance observed in the patients 220 outcome. (LDH R<sup>2</sup>=0.856, S.CRP R<sup>2</sup>=0.893) 221

# 222 Receiver Operating Characteristic Curve (ROC) and Area under the ROC Curve (AUC)

For better interpretation of these markers, it's possible utility in predicting the severity of disease (Figure: 3) and outcome (Figure: 4) of covid-19 patients, we plotted ROC curve. We calculated AUC and Cut off value for aforesaid markers. Here, we plotted ROC according to the Day of the measurement of the Parameters (ie: Day-0, Day-1, Day-3 and Day-7).

Among all inflammatory markers, LDH on all days has shown fair AUC values associated with severity ranging from 0.690 to 0.769. When these markers were used to find

AUC of ROC for identifying patients with or without Adverse Outcome (Death) in COVID-19 pneumonia, LDH and D-Dimer were found useful (Figure-4). AUC values for LDH were associated with adverse outcome are ranging from 0.639 to 0.831 while D-Dimer values were ranging from 0.630 to 0.763.

CRP and S. Ferritin were also analysed but their AUC, C-index were not found
 statistically significant in correlation with severity and outcome.

As per multivariate analysis of mortality and its association with risk factors-  $age \ge 50$ years (OR=3.34,95% CI 1.105: 10.074, *P*=0.032), Ischemic heart disease (OR=4.417, 95% CI 1.730: 11.272, *P*=0.002) and raised Troponin I, a cardiac injury bio- marker(OR=29.382, 95% CI 8.870: 97.326, *P*<0.001) were significantly associated with excess mortality in COVID -19 pneumonia patients. Male gender, hypertension, Diabetes Mellitus, Vitamin D deficiency (<30 ng/ml), raised D-Dimer (>1000microg/L) and raised uric acid(>6.5 mg/dl) have a trend of excess mortality but they were not found to be statistically significant (Figure-5).

# Predictors and its relationship with Severe COVID-19 Diseases & In-Hospital Death Mortality in COVID-19 Cases (Logistic Regression Analysis)

Binary Logistic Regression analysis was conducted in SPSS v25 & GraphPad Prism 244 v9. The results were statistically significant in predicting severity and death (Table-3). 245 Significant regression model (p<0.0001) was observed for predicating In-hospital Death 246 (Table-3). This model included LDH-D0, LDH-D1 and LDH-D7 during indoor care of the 247 patients. The pseudo  $R^2$  (Nagelkerke R Square) of the model is 0.578. The final logistic 248 regression predictive model formula found is, In-hospital Death= Intercept( $\beta 0$ ) + ( $\beta 1$ )LDH-D0 249 +  $(\beta 2)LDH-D1$  +  $(\beta 3)LDH-D7$  ie: In-hospital Death= (-7.333) + (-0.01305)LDH-D0 + 250 (0.009151)LDH-D1 + (0.01235)LDH-D7. Survival was coded as 0 and death was coded as 1. 251 The Predicting model shown AUC (C-Index) of 0.9290 (SE: 0.05023, CI: 0.8306 to 1.000, 252 p<0.0001) with Negative Predictive Power of 96% and Positive Predictive Power of 70%. 253

Regarding predicting severity, final logistic regression model formula found : Severe COVID-19 Cases= Intercept( $\beta$ 0) + ( $\beta$ 1)LDH\_D1 + ( $\beta$ 2)LDH\_D7 ie: Severe COVID-19 Cases= (-3.380)+( 0.004438)xLDH-D1+(0.005640)LDH-D7.Nonsevere category was coded as 0 and severe category was coded as 1. The Predicting model shown AUC (C-Index) of 0.7433(SE: 0.04526, CI: 0.6546 to 0.8320, p<0.0001) with Negative Predictive value of 67% and Positive Predictive Value of 71%.

- Hence, it can be inferred that LDH is one of the major markers which can help a 260
- clinician to predict severity and adverse outcome in severe covid-19 cases, than any other 261
- markers. 262
- 263

# 264 **DISCUSSION:**

Since the origin of SARS-CoV-2 caused COVID-19 infection, stakeholders alerted the whole world about the beginning of a new pandemic. Dearth of research papers flourished the scientific world publication media. A lot of information helped improved management of patients. But regionally relevant research always found lacking in strength of evidence. We attempted to fulfil some gap in these concern and tried to improve patient care.

#### 270 **Baseline characteristics:**

In our study, all mild cases (Nonsevere) were presented with mild symptoms and had good prognosis, they mostly recovered within 10 days of symptoms onset and discharged uneventfully. Rapid clinical deterioration was observed in severe cases in second week of illness onset, preceded with rise in inflammatory markers. So thorough risk assessment in early stage of disease might help in predicting disease severity.<sup>[8]</sup>

In our study, patients aged more than 50 years (n-135), 73(54.07%) having severe covid-19 illness (Gr-B+ Gr-C) and fatality rate was 14 (19.18%) among them. Which is almost 10% of all cases above 50 years. Death rates correlated with advanced age as found in other published studies. Overall case fatality rate was 13% in our study in patients aged over 50 years in having severe covid-19 disease. This rate was found higher in several other studies done in China.<sup>[9,10,11,12]</sup>

Gender difference in form of male predominance was seen in our study but fatality rate is almost equal in both genders. Reason for higher male predominance in the disease could be due to enhanced action of transmembrane protease serine 2 (TMPRSS2), which cleaves angiotensin converting enzyme-2 (ACE2) receptors and prime spike proteins.<sup>[13]</sup> Global data shows higher COVID 19 case fatality rate in male ranging from 1.0 to 3.5 in high income countries while in our country CFR is higher in women due to less detection ratio and delayed hospitalization.<sup>[9,14]</sup>

In our study, symptomatic patients with Rh positive blood types were more likely to be tested positive with COVID-19 compared to Rh negative type.<sup>[15]</sup>But it has no correlation with severity of COVID-19 illness. Studies in Italy and Spain demonstrated higher respiratory failure in "A+ve" blood group, while lower risk was found in "O+ve" blood group patients.<sup>[16]</sup> In ours study population, "B+ve" blood group was found to have higher number of deaths in comparison to other blood groups, although this needs further studies.

Most common comorbidity identified were Diabetes Mellitus 109(53.43%) followed by 295 Hypertension 106(51.96%) and Ischemic Heart Diseases 27(13.23%). Comorbidities were 296 almost similar in study by Adekunle et al.<sup>[17]</sup>Those who have more than one comorbidities, 297 mortality is high. Similar findings were also observed in a nationwide study conducted at 298 hospitals throughout China and other studies.<sup>[18,19]</sup> The odds ratio for Ischemic Heart Disease 299 300 was suggestive of poor outcome in COVID-19 cases. Tachypnoea on admission is associated with poor outcome. We observed that NonSevere group patients had less tachypnoea compared 301 to Severe & Survived and NonSurvived group of patients. It suggested that, respiratory rate on 302 admission is one of the prognostic indicators in severity of illness.<sup>[20]</sup> 303

# 304 Laboratory markers and Clinical Severity in COVID-19 Pneumonia:

Haemoglobin, Platelet count & total white blood cell count were not much different in all the categories on admission in current study population. In several studies higher Leukocyte count was found in critically ill patients. Lymphopenia and eosinopenia were observed in majority of cases.<sup>[21]</sup> The Neutrophil-Lymphocyte Ratio (NLR) on admission was found statistically different among these four groups (P=0.001). The ratio was higher among the severe categories of cases.<sup>[22]</sup>

Inflammatory markers were found to be increased in severe category of COIVD-19 cases, 311 which usually raised after day three of admission. Which is correlated with other published 312 studies.<sup>[23]</sup> As per Ji P et al<sup>[23]</sup>trend of elevated inflammatory markers were associated with 313 early identification, prediction of disease severity and adverse outcome in the form of death. 314 This study has analysed CRP, Ferritin, D-Dimer & LDH with Severity of the disease and 315 adverse outcome. This study observed strong C-index (AUC) for LDH post admission with 316 severity and death.<sup>[24]</sup>Among all inflammatory markers, LDH values after admission helped a 317 lot in predicting severity.<sup>[25]</sup> As per present study, LDH on day one of admission over 372unit/L 318 is approximately 70% Sensitive and Specific in predicting severity of covid-19 pneumonia. 319 This coincides with the data observed across several published studies. Same observation for 320 LDH on day one of admission was seen with death. LDH value above 468u/L was 77% 321 322 sensitive and 84% specific for death. Several studies suggested LDH having relation with early in-hospitaldeath.<sup>[26]</sup> Even D-Dimer on third day of admission and seventh day of admission are 323 related with early in-hospitaldeath.<sup>[27]</sup> D-Dimer on third day, more than 1500mcg/L is 87% 324 sensitive and 65% specific for death, while value on seventh day, more than 3500mcg/L is 69% 325 326 sensitive and 86% specific for early in-hospital death. These values correlated with Zhou F et al<sup>28</sup>and other studies.<sup>[29,30]</sup> 327

328 Deficiencies in certain micronutrients, in particular Vitamin-D deficiency was 329 discussed a lot in determining the severity of the disease, but was not found significantly 330 affecting the outcome in our study population. Several studies demonstrated its relation with 331 severity but it seems to be affected by several confounders.<sup>[31,32]</sup>

Advanced age (more than 50 years), Ischemic Heart Disease, Raised troponin are associated with excess mortality. Several studies demonstrated and expressed issues with raised troponin not to be used solely as a diagnostic marker of myocardial infarction and heart failure in COVID-19 illness. This might be due to injury caused by the virus to cardiac tissue rich in ACE-2 receptors.<sup>[33]</sup>

We, attempted to predict severity and in-hospital early outcome by formulating a regression formula. These needs to be validated on larger study population before using for routine clinical utility.

# 341 CONCLUSION:

- 342 Advanced age, male gender, IHD, Respiratory Rate & Heart Rate on admission were
- 343 associated with severe covid-19 illness. LDH & D-Dimer were associated with severe covid-
- 344 19 illness and early in-hospital death.

# 346 ETHICS STATEMENT:

This study was conducted independently without any external source of funding. Highest code of conduct was followed with utmost credibility ensured. The study was conducted after approval from Institutional Review Board (NHL Institutional review Board). Patient data were anonymized to maintain confidentiality of patient privacy.

352 References:

Lai C, Shih T, Ko W, Tang H, of PH-I journal, 2020 undefined. Severe acute
 respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID 19): The epidemic and the challenges. Elsevier
 https://www.sciencedirect.com/science/article/pii/S0924857920300674.

WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease
 (COVID-19) Dashboard. Accessed Feb 9, 2021. https://covid19.who.int/.

359 3. Sanders J, Monogue M, Jodlowski T, Jama JC-, 2020 undefined. Pharmacologic 360 treatments for coronavirus disease 2019 (COVID-19): a review. jamanetwork.com 361 https://jamanetwork.com/journals/jama/article-abstract/2764727.

362 4. (No Title). Accessed Feb 9, 2021.
363 https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated0307
364 2020.pdf.

365 5. Haimovich A, Ravindra N, ... SS-A of emergency, 2020 undefined. Development and
366 validation of the quick COVID-19 severity index: a prognostic tool for early clinical
367 decompensation. Elsevier

368 https://www.sciencedirect.com/science/article/pii/S0196064420305886.

Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of
 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
 JAMA - J Am Med Assoc 2020;323(16):1574–81. https://jamanetwork.com/.
 10.1001/jama.2020.5394

373 7. Ciceri F, Castagna A, Rovere-Querini P, et al. Early predictors of clinical outcomes of
374 COVID-19 outbreak in Milan, Italy. Clin Immunol 2020;217:108509.
375 10.1016/j.clim.2020.108509

8. Li L, Sun W, Han M, Ying Y, Monitor QW-MS, 2020 undefined. A Study on the
Predictors of Disease Severity of COVID-19. ncbi.nlm.nih.gov
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521067/.

379 9. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with
380 coronavirus disease 2019: Retrospective study. BMJ 2020;368.
381 https://www.bmj.com/content/368/bmj.m1091. 10.1136/bmj.m1091

10. Udwadia ZF, Tripathi AR, Nanda VJ, Joshi SR. Prognostic Factors for Adverse
Outcomes in COVID-19 Infection. J Assoc Physicians India 2020;68(7):62–6.

Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress
Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
JAMA Intern Med 2020;180(7):934.

387 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184.

388 10.1001/jamainternmed.2020.0994

389 12. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,

Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New

391 York City Area. JAMA - J Am Med Assoc 2020;323(20):2052–9. 10.1001/jama.2020.6775

Wambier CG, Goren A, Ossimetha A. Androgen-driven COVID-19 pandemic theory.
papers.ssrn.com https://ssrn.com/abstract=3571863. 10.13140/RG.2.2.21254.11848

14. Dehingia N, Raj A. Sex differences in COVID-19 case fatality: do we know enough?
thelancet.com 2021; www.thelancet.com/lancetgh. 10.1016/S2214-109X(20)30464-2

Latz CA, DeCarlo C, Boitano L, et al. Blood type and outcomes in patients with
COVID-19. Ann Hematol 2020;99(9):2113–8. https://pubmed.ncbi.nlm.nih.gov/32656591/.
10.1007/s00277-020-04169-1

16. Ellinghaus D, Degenhardt F, Bujanda L, MedRxiv MB-, 2020 undefined. The ABO
blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory
failure in an Italian-Spanish genome-wide association. medrxiv.org
https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1.full-text.

403 17. Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its Impact on Patients
404 with COVID-19. SN Compr Clin Med 2020;2(8):1069–76.
405 https://pubmed.ncbi.nlm.nih.gov/32838147/. 10.1007/s42399-020-00363-4

Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in
coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis
2020;94:91–5. 10.1016/j.ijid.2020.03.017

409 19. Guan W, Liang W, Zhao Y, ... HL-E, 2020 undefined. Comorbidity and its impact on
410 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir Soc
411 https://erj.ersjournals.com/content/55/5/2000547.short.

20. Izquierdo J, Ancochea J, ... JS-J of medical, 2020 undefined. Clinical Characteristics
and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19:
Retrospective Study Using Machine Learning. jmir.org
https://www.jmir.org/2020/10/e21801/.

416 21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
417 coronavirus in Wuhan, China. Elsevier
418 https://www.sciencedirect.com/science/article/pii/S0140673620301835.

419 22. Yang A, Liu J, Tao W, immunopharmacology HL-I, 2020 undefined. The diagnostic
420 and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Elsevier
421 https://www.sciencedirect.com/science/article/pii/S156757692030494X.

422 23. Ji P, Zhu J, Zhong Z, et al. Association of elevated inflammatory markers and severe
423 COVID-19: A meta-analysis. Medicine (Baltimore) 2020;99(47):e23315.
424 10.1097/MD.00000000023315

42524.Henry B, Aggarwal G, Wong J, ... SB-TA journal of, 2020 undefined. Lactate426dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A427pooledanalysis.Elsevier

428 https://www.sciencedirect.com/science/article/pii/S0735675720304368.

Zhou Y, Ding N, Yang G, Peng W, ... FT-A of, 2020 undefined. Serum lactate
dehydrogenase level may predict acute respiratory distress syndrome of patients with fever
infected by SARS-CoV-2. ncbi.nlm.nih.gov
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575930/.

Wu MY, Yao L, Wang Y, et al. Clinical evaluation of potential usefulness of serum
lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respir Res
2020;21(1). 10.1186/s12931-020-01427-8

436 27. Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality
437 in COVID-19 patients: A case control study. J Intensive Care 2020;8(1). 10.1186/s40560-020438 00466-z


28. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
2020;395(10229):1054–62. 10.1016/S0140-6736(20)30566-3

29. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 442 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc 443 2020;323(11):1061-9. https://pubmed.ncbi.nlm.nih.gov/32031570/. 10.1001/jama.2020.1585 444 30. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel 445 Pneumonia. Ν J 2020;382(13):1199-207. Coronavirus-Infected Engl Med 446 10.1056/nejmoa2001316 447 Maghbooli Z, Sahraian MA, Ebrahimi M, et al. Vitamin D sufficiency, a serum 25-31. 448 hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with 449


450 COVID-19 infection. PLoS One 2020;15(9 September).
451 https://pubmed.ncbi.nlm.nih.gov/32976513/. 10.1371/journal.pone.0239799

452 32. Munshi R, Hussein MH, Toraih EA, et al. Vitamin D insufficiency as a potential culprit
453 in critical COVID-19 patients. J. Med. Virol. 2021;93(2):733–40. Accessed Feb 9, 2021.
454 https://pubmed.ncbi.nlm.nih.gov/32716073/. 10.1002/jmv.26360

33. Tersalvi G, Vicenzi M, Calabretta D, LB-J of cardiac, 2020 undefined. Elevated
troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms.
Elsevier https://www.sciencedirect.com/science/article/pii/S1071916420303572.







		All	Mild	Moderate	Severe	Critical	
		n (%) mean <u>+</u> SD					
	0 to 49 years	69 (33.82%)	12 (35.29%)	16 (28.57%)	16 (41.03%)	25 (33.33%)	
	50 to 64 years	85 (41.67%)	12 (35.29%)	24 (42.86%)	14 (35.90%)	35 (46.67%)	
Age-Groups	>64 years	50 (24.51%)	10 (29.41%)	16 (28.57%)	9 (23.08%)	15 (20.00%)	
	All	204 (100%)	34 (100%)	56 (100.00%)	39 (100.00%)	75 (100.00%)	
	Female	53 (25.98%)	8 (23.53%)	12 (21.43%)	12 (30.77%)	21 (28.00%)	
Gender	Male	151 (74.02%)	26 (76.47%)	44 (78.57%)	27 (69.23%)	54 (72.00%)	
	All	204 (100%)	34 (16.67%)	56 (27.45%)	39 (19.12%)	75 (36.76%)	
DM		109 (53.43%)	12 (11.01%)	35 (32.11%)	25 (22.94%)	37 (33.94%)	
HTN		106 (51.96%)	12 (11.32%)	29 (27.36%)	24 (22.64%)	41 (38.68%)	
IHD		27 (13.24%)	2 (7.41%)	4 (14.81%)	5 (18.52%)	16 (59.26%)	
HR (on admission)		94.84 <u>+</u> 15.1	94.21 <u>+</u> 12.6	93.63 <u>+</u> 14.0	91.18 <u>+</u> 13.4	97.95 <u>+</u> 17.2	
SBP (on admission)		127.24 <u>+</u> 14.3	125.21 <u>+</u> 11.9	127.75 <u>+</u> 12.2	126.38 <u>+</u> 16.4	128.23 <u>+</u> 15.6	
DBP (on adm	DBP (on admission)		80.24 <u>+</u> 5.0	80.29 <u>+</u> 7.5	78.82 <u>+</u> 7.6	80.00 <u>+</u> 9.1	
RR (on admis	ssion)	19.68 <u>+</u> 6.0	16.44 <u>+</u> 1.3	18.95 <u>+</u> 4.1	20.38 <u>+</u> 5.6	21.33 <u>+</u> 7.8	
SpO2 (on adı	nission)	92.76 <u>+</u> 9.0	97.03 <u>+</u> 1.7	94.77 <u>+</u> 4.1	91.15 <u>+</u> 9.5	90.16 <u>+</u> 11.9	

462

Table-1 Baseline Demographic Details of Study population 463

465

466

#### Demographic and Clinical Presentation of study population

Characteristics		All	Mild to	o Moderate	Severe	to Critical	n vale	
Age	n=204	mean <u>+</u> SD	n=90	mean <u>+</u> SD	n=114	mean+SD	p-value	
All	204	55.09 <u>+</u> 13.21	90	52.64 <u>+</u> 13.71	114	57.02 <u>+</u> 13.71	0.153	
0-49 years	69 (34%)	40.73 <u>+</u> 7.51	38 (42%)	39.81 <u>+</u> 8.19	31 (27.19%)	41.87 <u>+</u> 6.53		
50-64 years	85 (42%)	56.94 <u>+</u> 3.97	34 (38%)	57.05 <u>+</u> 3.96	51 (44.73%)	56.86 <u>+</u> 4.01	0.071	
<u>&gt;</u> 65 years	50 (24%)	71.76 <u>+</u> 6.17	18 (20%)	73.84 <u>+</u> 4.11	32 (28.07%)	71.96 <u>+</u> 6.66		
Gender								
Men	151	(74.02%)	70 (	77.78%)	81 (7	71.05%)	0.277	
Women	53 (	25.98%)	20 (	22.22%)	33 (2	28.95%)	0.277	
Time to Hospitalisation (days)	1 to 38 days	6.00 <u>+</u> 4.60	1 to 38 days	5.62 <u>+</u> 4.58	1 to 32 days	5.61 <u>+</u> 4.80		
Length of Hospital Stay (days)	2 to 42 days	13.5 <u>+</u> 6.09	5 to 42 days	12 <u>+</u> 5.26	2 to 31 days	14.63 <u>+</u> 6.38		
Comorbidities								
HTN	106	(51.96%)	41 (	45.55%)	65 (5	0.104		
DM	109 (53.43%)		47 (52.22%)		62 (54.38%)		0.758	
IHD	27 (	13.23%)	6 (6.66%)		21 (18.42%)		0.014*	
<b>Clinical Parameters</b>								
Systolic BP (On Admission)	127.24+14.26		126.78+12.06		127.5	0.728		
Diastolic BP (On Admission)	79.	89+7.80	80.26+6.64		79.59+8.63		0.334	
HR (On Admission)	94.8	84 <u>+</u> 15.05	93.84+13.42		95.6	0.064		
RR (On Admission)	19.	68 <u>+</u> 5.97	18+3.50		21.0	0.010*		
SpO <sub>2</sub> (On Admission)	92.	76 <u>+</u> 8.96	95.	62+3.56	90.5	0.115		
Blood Groups								
A-	5 (	2.70%)	3 (	3.33%)	2 (1			
A+	46 (24.70%)		23 (	23 (25.56%)		23 (20.18%)		
AB+	20 (	10.80%)	10 (	11.11%)	10 (	0.718		
В-	4 (	2.20%)	1 (	1 (1.11%)		3 (2.63%)		
B+	60 (	32.30%)	20 (	22.22%)	40 (3			
0+	51 (	27.40%)	23 (	25.56%)	28 (2	24.56%)	]	

Table-1.1 Demographic Details and Baseline Clinical Characteristics 467

		All		NonSevere (Gr-A)		Severe & Survived (Gr-B)		Severe & NonSurvived (Gr-C)		p-value	Gr-A vs Gr-B	Gr-B vs Gr-C	Gr-A vs Gr-C
		n (%)	mean <u>+</u> SD	n (%)	mean <u>+</u> SD	n (%)	mean <u>+</u> SD	n (%)	mean <u>+</u> SD		p-value	p-value	p-value
Age-Groups	0 to 49 years	69 (33.8%)	40.7 <u>+</u> 7.5	28 (31.1%)	39.8 <u>+</u> 8.2	28 (32.2%)	42.8 <u>+</u> 5.3	13 (48.1%)	35.5 <u>+</u> 11.1		0.1039#	0.0343#	0.3445#
	50 to 64 years	85 (41.7%)	56.9 <u>+</u> 3.9	36 (40.0%)	57.0 <u>+</u> 3.9	39 (44.8%)	56.9 <u>+</u> 3.8	10 (37.0%)	56.5 <u>+</u> 4.7	< 0.001*	0.9266	0.7240	0.6917
	>64 years	50 (24.5%)	71.8 <u>+</u> 6.1	26 (28.9%)	71.3 <u>+</u> 5.3	20 (23.0%)	71.4 <u>+</u> 5.3	4 (14.8%)	73.1 <u>+</u> 8.9		0.5233	0.4999	0.9963
	All	204 (100%)	50.1 <u>+</u> 13.2	90 (44.1%)	52.6 <u>+</u> 13.7	87 (42.6%)	56.0 <u>+</u> 11.5	27 (13.2%)	60.1 <u>+</u> 12.9				
Gender	Female	53 (26	5%)	20 (2	22.2%)	26 (4	49.1%)	7 (1	3.2%)	0 500	0.040#	0.004	
	Male	151 (7	4%)	70 (77.8%)		61 (40.4%)		20 (13.2%)		0.509	0.248#	0.684#	0.702#
	All	204 (100%)		90 (44.1%)		87 (42.6%)		27 (13.2%)		0.5129*			
Blood Groups	A-	5 (2.7	%)	3 (6	0.0%)	1 (2	0.0%)	1 (2	0.0%)				
	A+	46 (24.	7%)	23 (50.0%)		16 (34.8%)		7 (15.2%)		0.440^	0.889	0.025	0.019
	AB+	20 (10.	8%)	10 (50.0%)		10 (50.0%)		0 (0.0%)					
	B-	4 (2.2	%)	1 (25.0%)		3 (75.0%)		0 (0.0%)					
	B+	60 (32.	3%)	20 (33.3%)		30 (50.0%)		10 (16.7%)					
	0+	51 (27.	4%)	23 (45.1%)		22 (43.1%)		6 (11.8%)					
	All	186 (10	0%)	80 (43.0%)		82 (44.1%)		24 (12.9%)					
DM		109 (53	.4%)	47 (52.2%)		51 (58.6%)		11 (40.7%)		0.254	0.395	0.106	0.296
HTN 106 (52.0%)		41 (45.6%)		47 (54.0%)		18 (66.7%)		0.138	0.260	0.251	0.055		
IHD		27 (13.2%)		6 (6.7%)		12 (13.8%)		9 (33.3%)		0.002	0.153	0.008	< 0.001
HR (on admission)		94.8 <u>+</u> 1	15.1	93.8 <u>+</u> 13.4		94.6	<u>+</u> 15.9	99.0 <u>+</u> 17.1		0.285	0.747	0.179	0.117
SBP (on admission)		127.2 <u>+</u>	14.3	126.	7 <u>+</u> 12.1	128.	4 <u>+</u> 15.2	125.1 <u>+</u> 17.9		0.541	0.463	0.302	0.593
DBP (on admission)		79.9 <u>+</u>	7.8	80.3 <u>+</u> 6.6		79.8 <u>+</u> 7.8		78.9 <u>+</u> 11.0		0.720	0.702	0.592	0.424
RR (on admiss	ion)	19.7 <u>+</u>	6.0	18	8 <u>+</u> 3.5	20.	7 <u>+</u> 6.2	22.	1 <u>+</u> 9.5	0.001	0.002	0.275	0.002
SpO2 (on admi	ssion)	92.8 <u>+</u>	9.0	95.	6 <u>+</u> 3.5	91.	2 <u>+</u> 9.8	88.1	<u>+</u> 14.4	< 0.001	0.001	0.104	< 0.001


\*Two-way ANOVA, #Unpaired t-test, ^Cramer's V

468


469 Table-1.2 Clinical Classification of COVID Patients in the Study


							Disease Clinic	al Categoi	ries					p- value
			Mild		Moderate			Severe			Critical			
		Mean <u>+</u>	<u>+</u> SD	N(%)	Mean <u>+</u> SD		N(%)	Mean <u>+</u> SD		N(%)	Mean <u>-</u>	<u>+</u> SD	N(%)	
Hb on Admission		13 <u>+</u>	1		13	3 <u>+</u> 2		12	2 <u>+</u> 2		13 <u>+</u>	2		0.294 (NS)
TC on Admission	1	5438 <u>+</u> 2058			7166 <u>+</u> 3168			7352 <u>+</u> 4236			8025 <u>+</u> 3952			0.288 (NS)
On admission NI	LR	5.15 <u>+</u> 3	3.88		6.96 <u>+</u> 7.22			7.93 <u>+</u> 5.43			7.81 <u>+</u> 6.86			0.350 (NS)
Platelet Count (Lakh)		242764 <u>+</u>	70568		252732 <u>+</u> 110253			269666 <u>+</u> 130071			249466 <u>+</u> 99587			0.703 (NS)
IL-6 on Admission		22 <u>+</u> 2	20	34(17%)*	24 <u>+</u> 22		56(27%)*	34 <u>+</u> 39		39(19%)*	101 <u>+</u> 177		75(37%)*	0.570 (NS)
NT Pro BNP	NT Pro BNP		224	34(17%)*	623 <u>+</u> 854		56(27%)*	484 <u>+</u> 858		39(19%)*	1659 <u>+</u> 2371		75(37%)*	0.467 (NS)
	A-			2(6.7%)#			1(2.0%)#			0(0.0%)#			2(2.9%)#	
	A+			9(30.0%)#			14(28.0%)#			7(19.4%)#			16(22.9%)#	
Dlaad Ground	AB+			4(13.3%)#			6(12.0%)#			5(13.9%)#			5(7.1%)#	0.718
Blood Groups	B-			0(0.0%)#			1(2.0%)#			0(0.0%)#			3(4.3%)#	(NS)
	B+			9(30.0%)#			11(22.0%)#			16(44.4%)#			24(34.3%)#	
	0+			6(20.0%)#			17(34.0%)#			8(22.2%)#			20(28.6%)#	
Chest X-ray findi	ings*													
B/L GGO		6(2.9%)		15(7.4%)		11(5.4%)		13(6.4%)		%)				
B/L GGO + Interstitial thickening			3(1.5%	)	1(0.5%)		1(0.5%)		1(0.5%)					
B/L whiteout lungs		3(1.5%)		1(0.5%)		0(0.0%)		6(2.9%)		0.166 (NS)				
GGO + Patchy o	consolidation		21(10.39	%)		36(17.6	%)	27(13.2%)		54(26.5%)		(113)		
Normal			1(0.5%	)		3(1.5%	6)		0(0.0%	6)		1(0.5%	%)	


472 Table-2 Disease Clinical Categories and Measured Laboratory Parameters




475 Figure-2 Inflammatory markers and Clinical Severity in COVID-19 Pneumonia







481 Figure-4 ROC Curve and AUC of Inflammatory Markers vs Adverse Outcome (Death)



484 Figure-5 Multivariate analysis of Mortality risk factors for patients with COVID-19 pneumonia

Bivariate Multiple Logistic Regression analysis predicting In-hospital Death											
	β	S.E.	Sig.	Exp(β)	95% CI						
LDH-D0	-0.0130	0.0040	0.0014	0.9870	0.977 to 0.994						
LDH-D1	0.0091	0.0033	0.0058	1.0090	1.004 to 1.018						
LDH-D7	0.0123	0.0031	< 0.0001	1.0120	1.007 to 1.020						
Constant	-7.3330	1.6760	< 0.0001	0.0006	1.275e-005 to 0.011						
Bivariate Multiple Lo	gistic Regres	sion analysis	predicting	Severe COVII	D-19 Disease						
	β	S.E.	Sig.	Exp(β)	95% CI						
LDH_D1	0.0044	0.0018	0.0170	1.0040	1.001 to 1.008						
LDH_D7	0.0056	0.0018	0.0025	1.0060	1.002 to 1.010						
Constant	-3.3800	0.9595	0.0004	0.0340	0.004 to 0.194						

Table-3 Bivariate Multiple Logistic regression analysis predicting In-hospital Death & Severe COVID-19 Disease